不同移植手术治疗角膜缘干细胞缺损的实验研究

目的探讨以人羊膜为载体培养的角膜缘干细胞，自体及异体移植治疗全角膜缘干细胞缺损。方法制作兔眼角膜缘干细胞完全缺损3个月的模型。实验动物随机分为自体移植组和异体移植组，前者取对侧眼角膜缘组织，后者取异体兔眼角膜缘组织，均以去除上皮细胞的羊膜基底膜为载体，培养12d后行角膜缘干细胞羊膜移植术。术后观察3个月，以角膜上皮染色、角膜浑浊和新生血管3项指标进行临床疗效评定，通过病理检查评估术后角膜上皮修复情况，印迹细胞学检查移植前后角膜上皮的细胞表型。结果体外培养的兔角膜缘干细胞可在羊膜上粘附生长并增生，体外培养12d可形成复层。自体移植组和部分异体移植组术后角膜上皮逐渐愈合，透明度提高，基质细胞浸润减轻，新生血管减退或消失。印迹细胞学检查显示：移植前角膜上皮细胞PAS阳性，而移植后转为阴性；组织病理学显示：移植前角膜上皮大部分缺损，移植后呈现角膜上皮结构。部分异体移植组术后出现了免疫排斥反应。结论兔自体角膜缘干细胞羊膜移植术可重建眼表；免疫排斥反应仍是异体角膜缘干细胞羊膜移植术失败的主要原因。     

组织工程角膜上皮治疗兔角膜缘干细胞缺乏症的研究

目的 评价以纤维凝胶膜为载体,体外培养自体角膜缘干细胞移植术治疗角膜缘干细胞缺乏症的临床效果。方法 制作兔眼角膜缘干细胞完全缺乏模型,取对侧眼角膜缘组织进行干细胞培养,并以纤维凝胶膜为载体制成组织工程角膜上皮。将实验动物随机分为4组,其中Ⅰ-Ⅲ组为实验组,行组织工程角膜上皮移植术,Ⅰ组移植术后观察3个月,Ⅱ组移植术后观察1个月,Ⅲ组移植术后观察2周。Ⅳ组为对照组,移植不含干细胞的凝胶膜,术后观察3个月。以角膜上皮染色、角膜混浊及新生血管3项指标进行临床疗效评定,通过病理检查评估术后不同时期角膜上皮修复情况,印迹细胞学检查移植前后角膜上皮的细胞表型,免疫组织化学染色观察角膜上皮特异性角蛋白K3、MUCSAC及转录因子p63在移植角膜上皮的表达。结果 实验组角膜上皮逐渐愈合,透明度提高,新生血管减退或消失;对照组角膜呈持续混浊,上皮缺损迁延不愈,最终大量新生血管长入,上皮结膜化。临床指标评分比较,差异有统计学意义（P=0．021）。角膜上皮印迹细胞学检查显示对照组为PAS（＋）的结膜细胞表型,而实验组上皮细胞PAS（-）。组织病理学显示实验组为正常角膜上皮结构,对照组为结膜化生的上皮,可见血管和杯状细胞。免疫组织化学显示实验组角膜上皮表达角膜上皮特异性角蛋白l（3（AE5）,不表达结膜特异性MUCSAC,在上皮基底部表达转录因子p63。对照组上皮持续表达MUCSAC。结论 组织工程角膜上皮移植术是一种有效的治疗角膜缘干细胞缺乏症的方法,可重建眼表,修复角膜上皮的损伤,抑制角膜上皮结膜化和新生血管。纤维凝胶膜为一种新型的组织工程材料,吸收快,透明度高,具有良好的组织相容性,是一种较理想的移植载体材料。（中华眼科杂志．2006．42：679-685）     

自体口腔黏膜上皮细胞培养眼表重建的实验研究

管计数、VEGF阳性表达量均最少.印迹细胞检杏:口腔黏膜细胞移植组角膜上皮未发现杯状细胞.结论 利用体外培养的自体口腔黏膜上皮细胞进行移植,可减少角膜新生血管的形成,其抑制新生血管的作用优于单纯羊膜移植抑制新生血管的作用.     

兔角膜缘上皮细胞培养后自体移植修复

目的：运用培养角膜缘上皮细胞联合人羊膜行自体移植的方法，观察植片修复兔眼角膜上皮的疗效。方法：选用健康新西兰白兔20只，制成右眼角膜缘干细胞缺乏的兔眼模型，其中12只兔行角膜缘上皮细胞培养联合羊膜自体移植，另外8只兔只进行单纯羊膜移植。术后每周对眼表情况进行评分，术后1mo眼角膜进行苏木素-伊红(HE)染色和透射电镜观察。结果：移植了含有自体角膜上皮细胞的兔眼，术后早期都形成了角膜上皮化并明显抑制了新生血管的再生，HE染色和电镜观察表明培养并移植的角膜上皮与正常的角膜上皮无明显差异；而只接受羊膜移植的兔眼，术后又出现角膜混浊和明显的新生血管，表明角膜表面被结膜上皮覆盖。结论：该方法术后早期可以恢复角膜上皮化，重建正常眼表，疗效明显优于单纯羊膜移植。     

人羊膜作为载体体外培养兔角膜上皮细胞移植治疗碱烧伤动物的实验研究

目的观察培养生长于人羊膜的兔角膜上皮细胞使其扩增并移植治疗角膜碱烧伤的效果。为培养角膜上皮细胞移植技术及应用于临床实践提供最佳的理论和实验依据。方法新西兰白兔30只（30眼）,随机分为3组（n=10）,右眼制成碱烧伤模型。A组：角膜上皮细胞羊膜移植组;B组单纯羊膜移植组;C组为对照组（碱烧伤后不作任何移植）。术后观察角膜透明度、角膜新生血管及上皮修复情况,裂隙灯显微镜照相记录。3组均于术后1周、2周、1个月及3个月时各取1眼角膜标本行病理组织检查。结果A组除1眼移植片在第7天脱落外,所有移植片在术后3d水肿消退,角膜逐渐透明。B组移植片持续水肿,眼前段炎性反应稍重,但较碱烧伤对照组轻。C组角结膜高度水肿浑浊,烧伤后观察3个月未发现角膜恢复透明现象。病理组织检查显示：A组角膜及周边上皮细胞为多层结构,角膜新生血管消失,基质的炎性细胞浸润减退;B组覆盖上皮细胞表现为完整上皮细胞型,C组角膜浑浊,新生血管及肉芽组织形成。结论人羊膜作载体体外培养兔角膜上皮细胞移植重建角膜基底膜和角膜上皮结构治疗兔碱烧伤后的角结膜损伤是一种合理有效的方法。     

口腔黏膜上皮培养与眼表移植的研究进展

人角膜上皮细胞由角膜缘干细胞不断补充, 从而维持眼表稳态及正常视觉功能。热化学烧伤、Stevens-Johnson综合征等眼表损伤或疾病可导致角膜缘干细胞缺损, 严重影响患者视力。当双眼角膜缘干细胞缺损时可考虑非角膜缘性自体上皮组织移植。口腔黏膜上皮细胞是眼表重建的重要种子细胞来源, 体外培养构建的细胞片已在临床应用中取得良好效果。本文围绕载体、培养条件及技术等影响口腔黏膜上皮片培养的各种因素, 以及细胞片应用于临床眼表移植的优缺点, 对利用口腔黏膜上皮治疗角膜缘干细胞缺损的研究进展进行综述, 以期为安全有效地重建眼表上皮提供研究方向。     

诱导人脐带间充质干细胞分化为角膜上皮样细胞的研究

背景眼表疾病导致的角膜盲已成为全球致盲性角膜疾病中的主要原因之一。随着组织工程技术的发展和进步,组织工程角膜为眼表疾病的治疗开辟了新的途径。目的观察体外培养的人脐带间充质干细胞（UC—MSCs）移植到兔角膜基质后的分化发育情况,探讨人UC-MSCs分化为角膜上皮细胞以及治疗兔角膜损伤的可行性。方法获取人脐带组织,采用Ⅳ型胶原酶消化法分离纯化人UC—MSCs并传代,取第3代细胞用于扩增和实验。流式细胞仪检测细胞的免疫表型及诱导成骨分化鉴定。24只新西兰大白兔按随机数字表法随机分为2个组,将人UC—MSCs接种于去上皮的猪角膜基质上,培养4d后行实验组兔左眼板层角膜移植;对照组以相同的手术方法单纯移植去上皮猪角膜基质。术后对角膜定期行活体激光共焦显微镜检查,并分别于术后2、4、8周摘除各组实验眼行组织病理学和免疫荧光检查,评价移植到兔角膜基质的人UC-MSCs的存活、分化以及移植局部的反应等;应用免疫荧光技术检测移植后角膜上皮细胞中角蛋白3（CK3）、CKl2以及转运蛋白G超家族成员（ABCG2）的表达。结果消化培养的人UC—MSCs呈圆形,细胞胞体较大,贴壁后细胞呈长梭形。培养获得的人UC—MSCs的细胞表型CD105^＋／CD29^＋／CD44^＋／CD34^-／CD45^-,并可诱导分化为成骨细胞。实验组人ISC—MSCs接种到去上皮猪角膜基质后贴附良好、生长迅速,术后植片在植床上存活良好,种植了人UC-MSCs的去上皮猪角膜移植到兔眼,可见实验组受体角膜较对照组透明,未见明显新生血管,在活体共焦显微镜下可见新生的角膜上皮样细胞,未发生免疫排斥反应。免疫荧光检测可见在重建的角膜上皮层检测到CK3及CKl2的阳性表达,而未见ABCG2的表达。结论将种植了人UC—MSCs的猪角膜基质移植到损伤的兔角膜后,人UC—MSCs可以存活、增生并分化为角膜上皮样细胞,可用于修复甚至重建损伤的角膜表层。     

羊膜培养兔角膜缘上皮细胞及自体移植--角膜缘干细胞缺损的治疗

目的　探讨以人羊膜为载体培养兔角膜缘上皮细胞及其自体移植治疗全角膜缘干细胞缺损。方法　在8只兔右眼用正庚醇脱上皮和角膜缘环切的方法构建全角膜缘干细胞缺损模型2月。其中6只兔为实验组,活体取左眼角膜缘浅层小块,置羊膜上常规和气_液培养42天后进行自体移植治疗右眼角膜缘干细胞缺损;2只兔为对照组,直接用解冻无细胞人羊膜移植治疗右眼角膜缘干细胞缺损。进行细胞和术眼活体观察、组织学观察和电镜观察。结果　角膜缘上皮细胞在羊膜上生长良好,形成复层,细胞间的联结结构存在,细胞与羊膜组织粘附牢固。实验组移植手术后角膜迅速上皮化,恢复角膜表面光滑和透明,组织学观察和电镜观察呈现生理角膜上皮层的结构特点。但眼睑闭合不全可导致手术失败。对照组术后出现角膜缘干细胞缺损导致的角膜病变。结论　以羊膜为载体培养角膜缘上皮细胞后自体移植可有效地治疗角膜缘干细胞缺损导致的角膜病变。     

组织工程角膜上皮移植治疗兔角膜碱烧伤的形态学观察

目的:探讨组织工程角膜上皮移植治疗角膜碱烧伤的疗效和时机。方法:1mol/LNaOH制作改良兔角膜碱烧伤模型21只42眼,分对照组和移植组,移植组分别在碱烧伤后1,3,6,9d(早)和14d(中)行自体或同种异体组织工程角膜上皮移植术,比较移植组及对照组烧伤后28d内眼表和组织病理学变化。结果:角膜碱烧伤后7d开始出现角膜上皮的大片脱落,14d角膜上皮大片脱落或溃疡发生率达72%,持续至28d,而移植组在28d时发生率仅为25%,大多获得完整的角膜上皮;烧伤后早期移植组角膜基质深层炎性细胞浸润和新生血管生长较对照组明显受到抑制,而中期移植组角膜基质层较对照组并无明显差异;28d内异体组织工程角膜上皮移植的免疫排斥反应并不大于自体移植。结论:自体或同种异体组织工程角膜上皮移植均可尽快恢复眼表完整性,且烧伤后早期移植效果明显优于中期移植。     

角膜上皮干细胞缺失动物模型的方法研究

目的:建立兔角膜上皮干细胞缺失动物模型,为人工生物角膜上皮实验研究奠定基础。方法:方法一,单纯去除角膜缘浅板层环周内外宽各2mm,深约100～150μm角膜组织;方法二,在方法一的基础上,再去除角膜中央浅板层组织约100～150μm。术后,裂隙灯显微镜下观察,以角膜混浊、上皮荧光素染色及新生血管为参数评价,3项参数得分之和为该动物时间点总评分。以角膜新生血管评分在3分以上,角膜上皮混浊在2分以上,采用印迹细胞法角膜面取材行角蛋白K3单克隆抗体间接免疫荧光法检测表达为阴性的。结果:单纯去除角膜缘的动物模型10眼有4眼成功(40%),从制作至成功平均时间29.5±1.3d。角膜缘联合角膜中央板层组织共同去除组,10眼均成功(100%),从制作至成功平均时间为15.8±0.8d,两组成功率对比差异有统计学意义(χ2=8.58,P<0.01);成功天数比较差异有统计学意义(t=24.5,P<0.01)。两组成功模型角膜采用印迹细胞法取材行角蛋白K3单克隆抗体间接免疫荧光法检测表达均为阴性。结论:采用角膜缘联合角膜中央上皮共同去除法制备角膜上皮干细胞缺乏模型成功率高,周期短,值得推广应用。     

角膜上皮干细胞定位及功能的研究进展

角膜上皮干细胞定位于角膜缘已被广泛认可,并被命名为角膜缘干细胞,且认为角膜缘干细胞在角膜上皮的自我更新和损伤修复中起重要作用.但近年来的一些研究却提出了与之相悖的观点:整个眼表层均含有寡能干细胞,且角膜缘干细胞在维持自我更新及稳态方面并未起到至关重要的作用.这些发现提示可能还有其他干细胞存在并维持着角膜上皮的自我更新,但也有人对这些新观点提出质疑.本文通过对最新研究的不同观点及证据的阐述,对近年来角膜上皮干细胞的定位及其功能等方面的进展作一综述.     

间充质干细胞在视网膜疾病中的临床应用展望

间充质干细胞(MSC)用于治疗视网膜疾病有两种移植方法:全身静脉注射和局部移植,后者具有更好的针对性。根据疾病不同,需要采用不同的MSC治疗策略:(1)MSC定向分化替代受损细胞,如光感受器细胞和视网膜色素上皮细胞;(2)利用其免疫抑制作用治疗自身免疫性葡萄膜视网膜炎;(3)利用其神经保护作用减轻或延缓视网膜组织损伤,如目前的视网膜色素变性、视网膜缺血再灌注损伤和青光眼动物模型;(4)转基因后的MSC移植靶向治疗,如脉络膜新生血管的治疗;(5)利用MSC抗炎和促进创伤愈合作用治疗多种视网膜疾病。迄今为止,其抑制葡萄膜视网膜炎进展以及视神经营养保护作用较为明确。但MSC在各种视网膜疾病中的疗效还需要严格评估,其发挥作用的机制尚未完全明了,不同研究结果差异较大。此外,MSC的移植途径和方法,治疗的远期效果及安全性也有待进一步评估。     

Characterization of extracellular matrix components in the limbal epithelial stem cell compartment

A specialized microenvironment or niche, which regulates maintenance, self-renewal, activation, and proliferation of stem cells by external signals, is one of the key prerequisites for stem cell function. However, the parameters determining the limbal stem cell niche are not yet defined. In order to characterize the role of basement membrane (BM) and extracellular matrix components in the generation of a microenvironmental niche for limbal stem and progenitor cells, we extensively analyzed the topographical variations of the BM zone of human ocular surface epithelia using immunohistochemistry and a large panel of antibodies to most of the presently described intrinsic and associated BM components. Apart from BM components uniformly expressed throughout all ocular surface epithelia (e.g. type IV collagen alpha5 and alpha6 chains, collagen types VII, XV, XVII, and XVIII, laminin-111, laminin-332, laminin chains alpha3, beta3,and gamma2, fibronectin, matrilin-2 and -4, and perlecan), the BM of the limbal epithelium shared many similarities with that of the conjunctival epithelium, including positive labelling for type IV collagen alpha1 and alpha2 chains, laminin alpha5, beta2, and gamma1 chains, nidogen-1 and -2, and thrombospondin-4, whereas type IV collagen alpha3, type V collagen, fibrillin-1 and -2, thrombospondin-1, and endostatin were present in the corneal BM, but lacking or more weakly expressed in the limbal and conjunctival BMs. As compared to both the corneal and conjunctival BMs, the limbal BM showed a markedly increased immunoreactivity for laminin alpha1, alpha2, beta1 chains, and agrin, and a specific but patchy immunoreactivity for laminin gamma3 chain, BM40/SPARC, and tenascin-C, which co-localized with ABCG2/p63/K19-positive and K3/Cx43/desmoglein/integrin-alpha2-negative cell clusters comprising putative stem and early progenitor cells in the basal epithelium of the limbal palisades. Components that were particularly expressed in the corneal-limbal transition zone included type XVI collagen, fibulin-2, tenascin-C/R, vitronectin, bamacan, chondroitin sulfate, and versican, all of which co-localized with vimentin-positive cell clusters comprising putative late progenitor cells in the basal epithelium. This pronounced heterogeneity of the BM in the limbal area, both in the region of limbal palisades and the corneal-limbal transition zone, appears to be involved in providing unique microenvironments for corneal epithelial stem and late progenitor cells. Identification of specific niche parameters might not only help to understand limbal stem cell regulation, but also to improve their selective enrichment and in vitro expansion for therapeutic strategies.     

Tissue engineered corneal epithelium derived from clinical-grade human embryonic stem cells

PurposeTo construct tissue engineered corneal epithelium from a clinical-grade human embryonic stem cells (hESCs) and investigate the dynamic gene profile and phenotypic transition in the process of differentiation.MethodsA stepwise protocol was applied to induce differentiation of clinical-grade hESCs Q-CTS-hESC-1 and construct tissue engineered corneal epithelium. Single cell RNA sequencing (scRNA-seq) analysis was performed to monitor gene expression and phenotypic changes at different differentiation stages. Immunostaining, real-time quantitative PCR and Western blot analysis were conducted to detect gene and protein expressions. After subcutaneous transplantation into nude mice to test the biosafety, the epithelial construct was transplanted in a rabbit corneal limbal stem cell deficiency (LSCD) model and followed up for eight weeks.ResultsThe hESCs were successfully induced into epithelial cells. scRNA-seq analysis revealed upregulation of ocular surface epithelial cell lineage related genes such as TP63, Pax6, KRT14, and activation of Wnt, Notch, Hippo, and Hedgehog signaling pathways during the differentiation process. Tissue engineered epithelial cell sheet derived from hESCs showed stratified structure and normal corneal epithelial phenotype with presence of clonogenic progenitor cells. Eight weeks after grafting the cell sheet onto the ocular surface of LSCD rabbit model, a full-thickness continuous corneal epithelium developed to fully cover the damaged areas with normal limbal and corneal epithelial phenotype.ConclusionThe tissue engineered corneal epithelium generated from a clinical-grade hESCs may be feasible in the treatment of limbal stem cell deficiency.     

干细胞移植治疗视网膜变性疾病的研究进展

视网膜变性疾病是一类与遗传相关的变性疾病,导致患者渐进性视觉丢失,是主要的致盲性眼病之一,其共同病理基础是视网膜光感受器细胞的变性、坏死和凋亡,然而目前尚无有效的治疗方法。细胞移植治疗是目前实验研究治疗视网膜变性疾病的主要方法之一。近年研究表明将感光前体细胞或视网膜色素上皮细胞移植到视网膜下腔或玻璃体内,可以延缓宿主感光细胞的凋亡、替代凋亡的感光细胞、挽救残存的视觉功能和修复视网膜结构。细胞移植治疗的一个很重要的问题是移植细胞的来源问题,目前主要的移植细胞来源是视网膜祖／干细胞、胚胎干细胞和诱导多潜能干细胞等。本文就干细胞移植治疗视网膜变性疾病的研究进展进行综述。     

【In Press】 Application of stem cell-derived retinal pigment epithelium in retinal degenerative diseases: present and future

Abstract: As a constituent of blood-retinal barrier and retinal outer segment (ROS) scavenger, retinal pigmented epithelium (RPE) is fundamental to normal function of retina. Malfunctioning of RPE contributes to the onset and advance of retinal degenerative diseases. Up to date, RPE replacement therapy is the only possible method to completely reverse retinal degeneration. Transplantation of human RPE stem cell-derived RPE (hRPESC-RPE) has shown some good results in animal models. With promising results in terms of safety and visual improvement, human embryonic stem cell-derived RPE (hESC-RPE) can be expected in clinical settings in the near future. Despite twists and turns, induced pluripotent stem cell-derived RPE (iPSC-RPE) is now being intensely investigated to overcome genetic and epigenetic instability. By far, only one patient has received iPSC-RPE transplant, which is a hallmark of iPSC technology development. During follow-up, no major complications such as immunogenicity or tumorigenesis have been observed. Future trials should keep focusing on the safety of stem cell-derived RPE (SC-RPE) especially in long period, and better understanding of the nature of stem cell and the molecular events in the process to generate SC-RPE is necessary to the prosperity of SC-RPE clinical application.     

Application of stem cell-derived retinal pigmented epithelium in retinal degenerative diseases: present and future

As a constituent of blood-retinal barrier and retinal outer segment (ROS) scavenger, retinal pigmented epithelium (RPE) is fundamental to normal function of retina. Malfunctioning of RPE contributes to the onset and advance of retinal degenerative diseases. Up to date, RPE replacement therapy is the only possible method to completely reverse retinal degeneration. Transplantation of human RPE stem cell-derived RPE (hRPESC-RPE) has shown some good results in animal models. With promising results in terms of safety and visual improvement, human embryonic stem cell-derived RPE (hESC-RPE) can be expected in clinical settings in the near future. Despite twists and turns, induced pluripotent stem cell-derived RPE (iPSC-RPE) is now being intensely investigated to overcome genetic and epigenetic instability. By far, only one patient has received iPSC-RPE transplant, which is a hallmark of iPSC technology development. During follow-up, no major complications such as immunogenicity or tumorigenesis have been observed. Future trials should keep focusing on the safety of stem cell-derived RPE (SC-RPE) especially in long period, and better understanding of the nature of stem cell and the molecular events in the process to generate SC-RPE is necessary to the prosperity of SC-RPE clinical application.     

Combined procedures in glaucoma surgery

The corneal limbus harbors corneal epithelial stem cells and contributes to the unique microenvironment of the stem cell niche. Corneal conditions, such as infections, tumors, immunological disorders, trauma, and chemical burns, often lead to the deficiency of the corneal stem cells, and subsequent vision loss. One key feature of limbal stem cell deficiency is corneal neovascularization. There is a delicate balance between pro-angiogenic and anti-angiogenic factors that, in a normal cornea, maintain an avascular state. A pro-angiogenic shift in this balance can occur due to various mechanisms, such as inflammation, gene mutations, physical breach in the limbal barrier, and decreased production of anti-angiogenic molecules. Currently available treatment options for limbal stem cell deficiency include allogeneic and autologous limbal transplants, and more recently, transplantation of alternative sources of epithelium, such as cultivated corneal and oral mucosal stem cells. Further studies are needed to investigate the combination of limbal and stem cell transplantation and concurrent anti-angiogenic therapy.     

Quantification of corneal neovascularization after ex vivo limbal epithelial stem cell therapy

AIM: To assess cultured limbal epithelial stem cell transplantation in patients with limbal stem cell deficiency by analyzing and quantifying corneal neovascularization.METHODS: This retrospective, interventional case series included eight eyes with total limbal stem cell deficiency. Ex vivo limbal epithelial stem cells were cultured on human amniotic membrane using an animal-free culture method. The clinical parameters of limbal stem cell deficiency, impression cytology, and quantification of corneal neovascularization were evaluated before and after cultured limbal stem cell transplantation. The area of corneal neovascularization, vessel caliber (VC), and invasive area (IA) were analyzed before and after stem cell transplantation by image analysis software. Best-corrected visual acuity (BCVA), epithelial transparency, and impression cytology were also measured.RESULTS: One year after surgery, successful cases showed a reduction (improvement) of all three parameters of corneal neovascularization [neovascular area (NA), VC, IA], while failed cases did not. NA decreased a mean of 32.31% (P=0.035), invasion area 29.37% (P=0.018) and VC 14.29% (P=0.072). BCVA improved in all eyes (mean follow-up, 76±21mo). Epithelial transparency improved significantly from 2.00±0.93 to 0.88±1.25 (P=0.014). Impression cytology showed that three cases failed after limbal epithelial stem cell therapy before 1y of follow-up.CONCLUSION: This method of analyzing and monitoring surface vessels is useful for evaluating the epithelial status during follow-up, as successful cases showed a bigger reduction in corneal neovascularization parameters than failed cases. Using this method, successful cases could be differentiated from failed cases.     

人牙周膜干细胞、脐带间充质干细胞对体外培养角膜缘干细胞的影响

目的　比较人牙周膜干细胞（ｈｕｍａｎｐｅｒｉｏｄｏｎｔａｌｌｉｇａｍｅｎｔｓｔｅｍｃｅｌｌｓ,ＨＰＤＬＳＣｓ）、人脐带间充质干细胞（ｈｕｍａｎｕｍｂｉｌｉｃａｌｃｏｒｄｍｅｓｅｎｃｈｙｍａｌｓｔｅｍｃｅｌｌｓ,ＨＵＣＭＳＣｓ）作为饲养层培养角膜缘干细胞（ｌｉｍｂａｌｓｔｅｍｃｅｌｌｓ,ＬＳＣｓ）的优越性,从而筛选出扩增ＬＳＣｓ的最佳饲养层。方法　体外分离培养ＨＰＤＬＳＣｓ、ＨＵＣＭＳＣｓ,诱导细胞成脂、成骨分化,并检测细胞表面标志物的表达;将兔ＬＳＣｓ与ＨＰＤＬＳＣｓ、ＨＵＣＭＳＣｓ、ＮＩＨ-３Ｔ３共培养和无饲养层单独培养,比较各组克隆形成率,免疫荧光比较各组ＬＳＣｓ克隆团ＡＢＣＢ５、ＩＰＯ１３、ＣＫ３／１２的表达情况。结果　体外培养ＨＰＤＬＳＣｓ、ＨＵＣＭＳＣｓ均可向脂肪、成骨细胞分化,两种细胞均高表达间充质来源的表面标志ＣＤ９０,不表达ＣＤ４５;三组饲养层与兔ＬＳＣｓ共培养均可形成小克隆团, ＨＰＤＬＳＣｓ组、ＨＵＣＭＳＣｓ组、ＮＩＨ-３Ｔ３组、无饲养层组克隆形成率分别为（４．９０±０．９６）％、（４．１０±０．５６）％、（４．６７±０．７６）％、（０．８３±０．３５）％,四组间总体比较差异有统计学意义（Ｆ＝２２．０４７,Ｐ＝０．００）;ＨＰＤＬＳＣｓ组、ＨＵＣＭＳＣｓ组与ＮＩＨ-３Ｔ３组的克隆形成率差异均无统计学意义（均为Ｐ＞０．０５）;ＨＰＤＬＳＣｓ组、ＨＵＣＭＳＣｓ组、ＮＩＨ-３Ｔ３组与无饲养层组间差异均有统计学意义（均为Ｐ＜０．０１）。免疫荧光化学检测三种饲养层ＬＳＣｓ标志物ＡＢＣＢ５、ＩＰＯ１３呈高表达,ＣＫ３／１２呈低表达。结论　ＨＰＤＬＳＣｓ、ＨＵＣＭＳＣｓ均可作为替代饲养层用以培养ＬＳＣｓ。